Recent introduction of two different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differences between the classifications will impact <1% of non-Hodgkin lymphomas.

This content is only available as a PDF.

Article PDF first page preview

Article PDF first page preview
You do not currently have access to this content.
Sign in via your Institution